
Northwest Biotherapeutics Inc
OTC:NWBO

Intrinsic Value
The intrinsic value of one
NWBO
stock under the Base Case scenario is
0.06
USD.
Compared to the current market price of 0.28 USD,
Northwest Biotherapeutics Inc
is
Overvalued by 79%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Northwest Biotherapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Northwest Biotherapeutics Inc
Balance Sheet Decomposition
Northwest Biotherapeutics Inc
Current Assets | 4.1m |
Cash & Short-Term Investments | 2.2m |
Other Current Assets | 1.9m |
Non-Current Assets | 22.7m |
PP&E | 20.4m |
Intangibles | 1.9m |
Other Non-Current Assets | 365k |
Free Cash Flow Analysis
Northwest Biotherapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Northwest Biotherapeutics Inc
Revenue
|
1.4m
USD
|
Operating Expenses
|
-67.9m
USD
|
Operating Income
|
-66.5m
USD
|
Other Expenses
|
-18.7m
USD
|
Net Income
|
-85.2m
USD
|
NWBO Profitability Score
Profitability Due Diligence
Northwest Biotherapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Score
Northwest Biotherapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
NWBO Solvency Score
Solvency Due Diligence
Northwest Biotherapeutics Inc's solvency score is 17/100. The higher the solvency score, the more solvent the company is.

Score
Northwest Biotherapeutics Inc's solvency score is 17/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NWBO Price Targets Summary
Northwest Biotherapeutics Inc
Dividends
Current shareholder yield for NWBO is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
NWBO
stock under the Base Case scenario is
0.06
USD.
Compared to the current market price of 0.28 USD,
Northwest Biotherapeutics Inc
is
Overvalued by 79%.